Biosafety testing of a kras TCR clinical product
Ended Awarded Last action
- Contract number
- HHSN26100017
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $55,987
Award facts
- Opportunity
-
- N02RC3600485 Solicitation number
- Biosafety Testing of GMP Master Cell Banks (MCB) and Retroviral Vectors for NCI Clinical Trials Award Notice · Posted Mar 7, 2013
- Contract value 100% obligated
- $55,986.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Quick answers
Who was awarded contract HHSN26100017?
HHSN26100017 was awarded to Bioreliance Corporation by National Cancer Institute (National Institutes of Health) on August 17, 2015.
How much is contract HHSN26100017 worth?
The government has obligated $55,987 on HHSN26100017.
Is contract HHSN26100017 an order under another contract?
Yes. HHSN26100017 is a delivery order under HHSN261201300026I, an indefinite delivery contract.
Was contract HHSN26100017 competed?
The extent of competition for HHSN26100017 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award